PUBLISHER: The Business Research Company | PRODUCT CODE: 2035927
PUBLISHER: The Business Research Company | PRODUCT CODE: 2035927
Exon Skipping Therapies Global Market Report 2026
Exon skipping therapies are RNA-based genetic treatments that modify pre-mRNA splicing to bypass disease-causing exons, allowing cells to produce a shorter yet partially functional protein. These therapies typically employ antisense oligonucleotides (ASOs) that bind to specific sequences in the pre-mRNA, masking the mutated exon so it is excluded during RNA processing.
The key product types of exon skipping therapies include antisense oligonucleotides, synthetic ribonucleic acid molecules, exon-targeted gene therapy kits, combination therapy formulations, and other variants. Antisense oligonucleotides are short, synthetic strands designed to bind specific RNA sequences and modify gene expression to restore functional protein production. Routes of administration include oral, intravenous, subcutaneous, and others, with distribution via direct sales, distributors, online pharmacies, and other channels. Applications include Duchenne muscular dystrophy, Becker muscular dystrophy, spinal muscular atrophy, other inherited diseases, and others, serving hospitals and clinics, research institutes, biopharmaceutical companies, specialty genetic centers, and other end users.
Tariffs on imported raw materials such as synthetic nucleotides, viral vectors, and specialized laboratory equipment are impacting the exon skipping therapies market by increasing manufacturing and R&D costs, particularly affecting antisense oligonucleotides and exon-targeted gene therapy kits. Regions reliant on cross-border biotech supply chains, including North America and parts of Europe and Asia-Pacific, are most affected. Hospitals, research institutes, and biopharmaceutical companies may experience higher procurement costs. However, tariffs are also encouraging localized manufacturing of RNA-based therapeutics and strengthening domestic biotechnology ecosystems, supporting long-term regional self-reliance.
The exon skipping therapies market research report is one of a series of new reports from The Business Research Company that provides exon skipping therapies market statistics, including exon skipping therapies industry global market size, regional shares, competitors with a exon skipping therapies market share, detailed exon skipping therapies market segments, market trends and opportunities, and any further data you may need to thrive in the exon skipping therapies industry. This exon skipping therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The exon skipping therapies market size has grown exponentially in recent years. It will grow from $2.34 billion in 2025 to $2.81 billion in 2026 at a compound annual growth rate (CAGR) of 20.1%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, growing research in RNA splicing mechanisms, early regulatory approvals for antisense therapies, rising funding for rare disease research, expanding biotechnology partnerships.
The exon skipping therapies market size is expected to see exponential growth in the next few years. It will grow to $5.9 billion in 2030 at a compound annual growth rate (CAGR) of 20.4%. The growth in the forecast period can be attributed to adoption of personalized genetic medicine, increasing pipeline of exon-targeted therapies, rising investment in advanced delivery systems, expanding approvals across inherited neuromuscular disorders, increasing collaboration between research institutes and biopharmaceutical companies. Major trends in the forecast period include advancements in antisense oligonucleotide chemistry, increasing focus on rare genetic disorders, expansion of combination genetic therapy approaches, growing investment in RNA-based therapeutics pipelines, rising clinical trials for exon-specific mutations.
The growing prevalence of genetic disorders is expected to boost the growth of the exon skipping therapies market over the forecast period. Genetic disorders are conditions resulting from abnormalities in an individual's genetic material (DNA), including single-gene mutations and chromosomal alterations that can lead to inherited or acquired diseases. The observed increase in the prevalence of genetic disorders is primarily due to advancements in diagnostic technologies and the expanding application of genetic testing and newborn screening programs, which enable earlier and more precise identification of previously undiagnosed cases. Exon skipping therapies are developed to target specific genetic mutations by selectively skipping faulty exons during messenger RNA (mRNA) processing, restoring the production of partially or fully functional proteins. This targeted therapeutic method directly addresses the underlying molecular causes of certain genetic disorders, particularly rare and previously untreatable conditions, generating significant clinical and commercial interest. For example, in October 2024, according to the National Health Service (NHS) England, a UK-based government department, a pioneering newborn screening program was launched across NHS hospitals to test hundreds of newborns for over 200 rare genetic conditions, with plans to expand testing to up to 100,000 babies across England. Therefore, the growing prevalence of genetic disorders is driving the growth of the exon skipping therapies market.
Leading companies operating in the exon skipping therapies market are increasingly focusing on the development of innovative treatment modalities such as investigational antibody-oligonucleotide conjugate (AOC) therapies to improve targeted delivery and enhance dystrophin production in patients with Duchenne muscular dystrophy (DMD). AOC therapies represent a next-generation approach that combines a monoclonal antibody with a synthetic oligonucleotide, enabling the targeted delivery of exon-skipping molecules directly to muscle cells. For example, in July 2025, Avidity Biosciences Inc., a U.S.-based biotechnology company, received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for delpacibart zotadirsen (del-zota), an investigational AOC therapy for the treatment of DMD in patients with mutations amenable to exon 44 skipping. Del-zota consists of a proprietary monoclonal antibody conjugated to phosphorodiamidate morpholino oligomers (PMOs), which promote exon 44 skipping during mRNA processing. The therapy is currently in Phase 2 clinical development, with plans for regulatory submission supported by robust biomarker and clinical efficacy data. Such advancements underscore the growing emphasis on differentiated delivery platforms within the exon skipping therapies market and highlight how AOC technologies are shaping the future of precision treatments for genetic neuromuscular disorders.
In November 2025, Biogen Inc., a US-based healthcare biotechnology company, acquired Alcyone Therapeutics for an undisclosed amount. With this acquisition, Biogen aimed to enhance its drug delivery technology capabilities by incorporating Alcyone's thecaflex DRx intrathecal delivery platform to improve patient-centric administration of neurologic therapies and strengthen its pipeline execution. Alcyone Therapeutics is a US-based clinical-stage biotechnology company specializing in the development of exon-skipping therapies.
Major companies operating in the exon skipping therapies market are Daiichi Sankyo Company Limited, BioMarin Pharmaceutical Inc., Sarepta Therapeutics, Nippon Shinyaku Co. Ltd., Ionis Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals Inc., Entrada Therapeutics Inc., Wave Life Sciences, PepGen Inc., ProQR Therapeutics NV, NS Pharma Inc., Genethon, Astellas Gene Therapies, SQY Therapeutics, AUM Biotech Inc., Cure Rare Disease Inc., Autotelic Bio Inc., Dyne Therapeutics, Skip Therapeutics.
North America was the largest region in the exon skipping therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exon skipping therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the exon skipping therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The exon skipping therapies market consists of sales of eteplirsen, golodirsen, viltolarsen, and casimersen. Values in this market are "factory gate" values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services such as formulation development, regulatory compliance support, clinical trial assistance, and technical guidance sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Exon Skipping Therapies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses exon skipping therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for exon skipping therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The exon skipping therapies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
- Markets Covered:1) By Product Type: Antisense Oligonucleotides; Synthetic Ribonucleic Acid Molecules; Exon-Targeted Gene Therapy Kits; Combination Therapy Formulations; Other Product Types
- 2) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Route Of Administration
- 3) By Distribution Channel: Direct Sales; Distributors; Online Pharmacies; Other Distribution Channel
- 4) By Application: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Spinal Muscular Atrophy; Other Inherited Diseases; Other Applications
- 5) By End-User: Hospitals And Clinics; Research Institutes; Biopharmaceutical Companies; Specialty Genetic Centers; Other End Users
- Subsegments:
- 1) By Antisense Oligonucleotides: Phosphorodiamidate Morpholino Oligonucleotides; Peptide Conjugated Oligonucleotides; Gapmer Oligonucleotides; Steric Blocking Oligonucleotides; Splice Modulating Oligonucleotides
- 2) By Synthetic Ribonucleic Acid Molecules: Messenger Ribonucleic Acid Molecules; Small Interfering Ribonucleic Acid Molecules; Guide Ribonucleic Acid Molecules; Modified Ribonucleic Acid Molecules; Therapeutic Ribonucleic Acid Constructs
- 3) By Exon-Targeted Gene Therapy Kits: Viral Vector Delivery Kits; Non-Viral Delivery Kits; Plasmid-Based Gene Therapy Kits; Targeted Editing Delivery Kits; Tissue Specific Delivery Kits
- 4) By Combination Therapy Formulations: Gene Therapy And Drug Combination; Oligonucleotide And Small Molecule Combination; Multi-Target Genetic Therapy; Supportive Protein Therapy Combination; Sequential Genetic Therapy Formulations
- 5) By Other Product Types: Peptide Based Genetic Modulators; Nanoparticle Delivery Formulations; Lipid Based Delivery Systems; Targeted Molecular Complexes; Personalized Genetic Therapy Formats
- Companies Mentioned: Daiichi Sankyo Company Limited; BioMarin Pharmaceutical Inc.; Sarepta Therapeutics; Nippon Shinyaku Co. Ltd.; Ionis Pharmaceuticals Inc.; PTC Therapeutics; Ionis Pharmaceuticals Inc.; Entrada Therapeutics Inc.; Wave Life Sciences; PepGen Inc.; ProQR Therapeutics NV; NS Pharma Inc.; Genethon; Astellas Gene Therapies; SQY Therapeutics; AUM Biotech Inc.; Cure Rare Disease Inc.; Autotelic Bio Inc.; Dyne Therapeutics; Skip Therapeutics.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: Word, PDF or Interactive Report
- + Excel Dashboard
- Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
Table of Contents
1. Executive Summary
- 1.1. Key Market Insights (2020-2035)
- 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
- 1.3. Major Factors Driving the Market
- 1.4. Top Three Trends Shaping the Market
2. Exon Skipping Therapies Market Characteristics
- 2.1. Market Definition & Scope
- 2.2. Market Segmentations
- 2.3. Overview of Key Products and Services
- 2.4. Global Exon Skipping Therapies Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
- Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
- 2.4.4. Market Attractiveness Scoring and Interpretation
- 2.4.5. Strategic Implications and Recommendations
3. Exon Skipping Therapies Market Supply Chain Analysis
- 3.1. Overview of the Supply Chain and Ecosystem
- 3.2. List Of Key Raw Materials, Resources & Suppliers
- 3.3. List Of Major Distributors and Channel Partners
- 3.4. List Of Major End Users
4. Global Exon Skipping Therapies Market Trends And Strategies
- 4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Immersive Technologies (AR/VR/XR) & Digital Experiences
- 4.2. Major Trends
- 4.2.1 Advancements In Antisense Oligonucleotide Chemistry
- 4.2.2 Increasing Focus On Rare Genetic Disorders
- 4.2.3 Expansion Of Combination Genetic Therapy Approaches
- 4.2.4 Growing Investment In RNA-Based Therapeutics Pipelines
- 4.2.5 Rising Clinical Trials For Exon-Specific Mutations
5. Exon Skipping Therapies Market Analysis Of End Use Industries
- 5.1 Hospitals And Clinics
- 5.2 Research Institutes
- 5.3 Biopharmaceutical Companies
- 5.4 Specialty Genetic Centers
- 5.5 Academic Medical Centers
6. Exon Skipping Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Exon Skipping Therapies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
- 7.1. Global Exon Skipping Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 7.2. Global Exon Skipping Therapies Market Size, Comparisons And Growth Rate Analysis
- 7.3. Global Exon Skipping Therapies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
- 7.4. Global Exon Skipping Therapies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Exon Skipping Therapies Total Addressable Market (TAM) Analysis for the Market
- 8.1. Definition and Scope of Total Addressable Market (TAM)
- 8.2. Methodology and Assumptions
- 8.3. Global Total Addressable Market (TAM) Estimation
- 8.4. TAM vs. Current Market Size Analysis
- 8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Exon Skipping Therapies Market Segmentation
- 9.1. Global Exon Skipping Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Antisense Oligonucleotides, Synthetic Ribonucleic Acid Molecules, Exon-Targeted Gene Therapy Kits, Combination Therapy Formulations, Other Product Types
- 9.2. Global Exon Skipping Therapies Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Oral, Intravenous, Subcutaneous, Other Route Of Administration
- 9.3. Global Exon Skipping Therapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Direct Sales, Distributors, Online Pharmacies, Other Distribution Channel
- 9.4. Global Exon Skipping Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy, Other Inherited Diseases, Other Applications
- 9.5. Global Exon Skipping Therapies Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Hospitals And Clinics, Research Institutes, Biopharmaceutical Companies, Specialty Genetic Centers, Other End Users
- 9.6. Global Exon Skipping Therapies Market, Sub-Segmentation Of Antisense Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Phosphorodiamidate Morpholino Oligonucleotides, Peptide Conjugated Oligonucleotides, Gapmer Oligonucleotides, Steric Blocking Oligonucleotides, Splice Modulating Oligonucleotides
- 9.7. Global Exon Skipping Therapies Market, Sub-Segmentation Of Synthetic Ribonucleic Acid Molecules, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Messenger Ribonucleic Acid Molecules, Small Interfering Ribonucleic Acid Molecules, Guide Ribonucleic Acid Molecules, Modified Ribonucleic Acid Molecules, Therapeutic Ribonucleic Acid Constructs
- 9.8. Global Exon Skipping Therapies Market, Sub-Segmentation Of Exon-Targeted Gene Therapy Kits, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Viral Vector Delivery Kits, Non-Viral Delivery Kits, Plasmid-Based Gene Therapy Kits, Targeted Editing Delivery Kits, Tissue Specific Delivery Kits
- 9.9. Global Exon Skipping Therapies Market, Sub-Segmentation Of Combination Therapy Formulations, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Gene Therapy And Drug Combination, Oligonucleotide And Small Molecule Combination, Multi-Target Genetic Therapy, Supportive Protein Therapy Combination, Sequential Genetic Therapy Formulations
- 9.10. Global Exon Skipping Therapies Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Peptide Based Genetic Modulators, Nanoparticle Delivery Formulations, Lipid Based Delivery Systems, Targeted Molecular Complexes, Personalized Genetic Therapy Formats
10. Exon Skipping Therapies Market Regional And Country Analysis
- 10.1. Global Exon Skipping Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- 10.2. Global Exon Skipping Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Exon Skipping Therapies Market
- 11.1. Asia-Pacific Exon Skipping Therapies Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Exon Skipping Therapies Market
- 12.1. China Exon Skipping Therapies Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 12.2. China Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Exon Skipping Therapies Market
- 13.1. India Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Exon Skipping Therapies Market
- 14.1. Japan Exon Skipping Therapies Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 14.2. Japan Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Exon Skipping Therapies Market
- 15.1. Australia Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Exon Skipping Therapies Market
- 16.1. Indonesia Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Exon Skipping Therapies Market
- 17.1. South Korea Exon Skipping Therapies Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 17.2. South Korea Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Exon Skipping Therapies Market
- 18.1. Taiwan Exon Skipping Therapies Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 18.2. Taiwan Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Exon Skipping Therapies Market
- 19.1. South East Asia Exon Skipping Therapies Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 19.2. South East Asia Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Exon Skipping Therapies Market
- 20.1. Western Europe Exon Skipping Therapies Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 20.2. Western Europe Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Exon Skipping Therapies Market
- 21.1. UK Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Exon Skipping Therapies Market
- 22.1. Germany Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Exon Skipping Therapies Market
- 23.1. France Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Exon Skipping Therapies Market
- 24.1. Italy Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Exon Skipping Therapies Market
- 25.1. Spain Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Exon Skipping Therapies Market
- 26.1. Eastern Europe Exon Skipping Therapies Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 26.2. Eastern Europe Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Exon Skipping Therapies Market
- 27.1. Russia Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Exon Skipping Therapies Market
- 28.1. North America Exon Skipping Therapies Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 28.2. North America Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Exon Skipping Therapies Market
- 29.1. USA Exon Skipping Therapies Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 29.2. USA Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Exon Skipping Therapies Market
- 30.1. Canada Exon Skipping Therapies Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 30.2. Canada Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Exon Skipping Therapies Market
- 31.1. South America Exon Skipping Therapies Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 31.2. South America Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Exon Skipping Therapies Market
- 32.1. Brazil Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Exon Skipping Therapies Market
- 33.1. Middle East Exon Skipping Therapies Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 33.2. Middle East Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Exon Skipping Therapies Market
- 34.1. Africa Exon Skipping Therapies Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 34.2. Africa Exon Skipping Therapies Market, Segmentation By Product Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Exon Skipping Therapies Market Regulatory and Investment Landscape
36. Exon Skipping Therapies Market Competitive Landscape And Company Profiles
- 36.1. Exon Skipping Therapies Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
- 36.2. Exon Skipping Therapies Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
- 36.3. Exon Skipping Therapies Market Company Profiles
- 36.3.1. Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Sarepta Therapeutics Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Nippon Shinyaku Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
37. Exon Skipping Therapies Market Other Major And Innovative Companies
- PTC Therapeutics, Entrada Therapeutics Inc., Wave Life Sciences, PepGen Inc., ProQR Therapeutics NV, NS Pharma Inc., Genethon, Astellas Gene Therapies, SQY Therapeutics, AUM Biotech Inc., Cure Rare Disease Inc., Autotelic Bio Inc., Dyne Therapeutics, Skip Therapeutics
38. Global Exon Skipping Therapies Market Competitive Benchmarking And Dashboard
39. Upcoming Startups in the Market
40. Key Mergers And Acquisitions In The Exon Skipping Therapies Market
41. Exon Skipping Therapies Market High Potential Countries, Segments and Strategies
- 41.1 Exon Skipping Therapies Market In 2030 - Countries Offering Most New Opportunities
- 41.2 Exon Skipping Therapies Market In 2030 - Segments Offering Most New Opportunities
- 41.3 Exon Skipping Therapies Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies
42. Appendix
- 42.1. Abbreviations
- 42.2. Currencies
- 42.3. Historic And Forecast Inflation Rates
- 42.4. Research Inquiries
- 42.5. The Business Research Company
- 42.6. Copyright And Disclaimer
